Posted by & filed under Company Analysis, Financial analysis, Governments & Regulators, Growth & Valuation.

Description: In July 2014, Dimitry Khmelnitsky advised investors to sell Valeant Pharmaceuticals International Inc. and then watched the stock double in a year. “It was very painful,” Khmelnitsky, an analyst at Veritas Investment Research Corp., said in an telephone interview from his office in Toronto. “What I felt was pain.”

Source: – video report

Date: Mar 02, 2016


Questions for Discussions:

  • What does this report say about the reasons for Valeant stock movements over the past few years?
  • What lessons are there for investors and financial managers?
  • What should investors do now?

Leave a Reply

Your email address will not be published. Required fields are marked *